Reveleer vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 52)
Reveleer logo

Reveleer

ChallengerHealthcare Revenue Cycle & Health IT

Risk Adjustment & Quality Management

AI-powered risk adjustment, quality management, and HEDIS analytics for health plans and ACOs; raised $60M+. Glendale CA;

AI VisibilityBeta
Overall Score
C52
Category Rank
#324 of 596
AI Consensus
69%
Trend
stable
Per Platform
ChatGPT
47
Perplexity
46
Gemini
55

About

Reveleer is a health IT company that provides AI-powered solutions for risk adjustment, quality management, and care gap closure to health plans, ACOs, and provider organizations. Founded in 2014 and headquartered in Glendale, California, Reveleer has raised more than $60 million in growth capital. Its platform combines intelligent document ingestion, natural language processing, and workflow automation to help payers accurately capture risk and close quality gaps at scale, supporting programs like Medicare Advantage, Medicaid Managed Care, and ACA Marketplace.\n\nThe company's core capabilities include automated medical record retrieval, AI-assisted HCC coding review, HEDIS measure tracking, and clinical analytics that surface actionable insights across member populations. Reveleer's platform is designed to serve the full risk adjustment lifecycle from retrospective chart review through prospective care coordination, enabling health plans to improve risk accuracy while simultaneously identifying members who need targeted outreach for quality improvement.\n\nReveleer competes in a market increasingly defined by the financial importance of accurate risk scoring in value-based care contracts. The company has expanded its technology to include an integrated analytics layer that connects risk adjustment and quality data, helping health plans understand the intersection between clinical gaps and revenue impact. Its cloud-native architecture and configurable workflow engine make it adaptable to the specific program requirements of national and regional health plans.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

52
Overall Score
81
#324
Category Rank
#17
69
AI Consensus
71
stable
Trend
stable
47
ChatGPT
80
46
Perplexity
75
55
Gemini
77
51
Claude
86
58
Grok
85

Key Details

Category
Risk Adjustment & Quality Management
General
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Reveleer
Risk Adjustment & Quality Management

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.